HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Information Disclosure Issues Challenge FDA Transparency Task Force

This article was originally published in The Tan Sheet

Executive Summary

FDA questions whether to disclose information on product applications that a company abandons before approval or in some cases on applications in which review is still pending

You may also be interested in...



FDA Launches System To Track Performances of Its Offices

For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible

Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings.

FDA To Address Industry Questions In Transparency Effort

FDA has expanded its transparency initiative to cover an unanticipated area - explaining how the agency works to the industries it regulates

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS135750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel